In a randomized , open-label , multicenter , phase III study , patients with previously untreated predominantly clear-cell mRCC were randomly assigned , stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group , to receive the combination of either temsirolimus ( @ mg intravenously , weekly ) or IFN ( @ MIU subcutaneously thrice weekly ) with bevacizumab ( @ mg/kg intravenously , every @ weeks ) .